Enrolling Patients in Two Registration-Directed Trials for Lead Candidate, Oral Fadraciclib –
– Expecting Key Data Readouts for Oral Fadraciclib in 2022 –
– Planning to Launch Two Registration-Directed Studies for Differentiated Oral PLK1 Inhibitor, CYC140 –
https://finance.yahoo.com/news/cyclacel-pharmaceuticals-reviews-2021-achievements-120000726.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.